The role of major histocompatibility gene products (i.e., HLA molecules) in rendering tumor cells resistant to natural killer (NK) cell-mediated lysis was investigated by using mouse monoclonal antibodies to bind and mask HLA or non-HLA gene products on 
Introduction
The presence of natural killer (NK)' cells in normal individuals, has led investigators to unravel its normal in vivo significance and, in particular, elucidate mechanisms that render tumor cells susceptible to lysis by such cells. Unlike other forms of immune-mediated lysis, and hence intriguing, is the observation that NK-mediated lysis of susceptible tumor targets will occur in the absence of prior immunization or sensitization (1) . It is possible, therefore, that NK mediated lysis may subserve a more primordial host defense against malignancy as has been suggested (2).
Enhanced susceptibility or resistance of tumor cells to NK mediated lysis cannot be attributed to any structure (or receptor) on the target cell membrane (3) . Recent studies would indicate that lack ofmajor histocompatibility (MHC) antigens, especially class I antigens, renders certain tumor cells more susceptible to NK-mediated lysis (4) (5) (6) (7) . Murine lymphoma cells when selected for loss of H-2 expression were shown to be less malignant when compared to the corresponding wild type control expressing H-2 antigens. Depletion of NK cells from these mice enhanced malignant potential of the H-2 deficient variant and subsequent in vitro assays demonstrated that the H-2 deficient variant and not the wild type was susceptible to NK lysis (4, 5) . Harel-Bellan and her coinvestigators using a human Epstein Barr virus-transformed B cell line nicely demonstrated in an in vitro system that variants of this cell line, when perturbed in the expression of class I molecules, was particularly sensitive to NK lysis (6) . However, in both these studies, there is a possibility, though remote, that susceptibility to NK-mediated lysis is caused by altered expression of other nonclass I molecules as a direct result of mutation in the MHC or as an indirect effect of a reduced class I antigen expression as has been suggested by Storkus et al. (7) .
Other investigators using different murine cell lines, transformed by adenoviruses or chemical mutagens, to alter expression of class I antigens, have been unable to confirm the role of class I MHC antigens in protecting against NK-mediated lysis (8-1 1) . In fact, these investigators found that lack of class I antigens was associated with resistance to NK cell killing (8) (9) (10) .
It is possible that these conflicting observations could have arisen if the different maneuvers used to alter class I antigen expression in the different tumor cell lines variably altered expression ofother membrane molecules involved in NK lysis. After all, NK-mediated lysis is a complex process requiring recognition, target cell binding, and lysis of target cells as a result of activating the lytic processes in the effector cells.
In these experiments we used a different approach by utilizing murine monoclonal antibodies to specifically bind and hence "mask" HLA or non-HLA molecules expressed on human tumor targets. We present data to confirm previous observations and show that both class I and II HLA molecules are important in maintaining tumor target cell resistance towards NK cytotoxicity especially with regard to lymphoid-derived tumors. Additionally, our studies indicate that with certain solid tumors, resistance to NK-mediated lysis cannot be entirely explained on the basis of membrane HLA molecules.
Methods
Cell lines. All cell lines used grow in suspension. Cells were grown in Antibody dependent cellular cytotoxicity (ADCC). This assay was performed using techniques identical to that used for the NK assays. Two antibody-target combinations that were previously well studied by other investigators were used as controls (20, 21) . FeMx melanoma cell line and the rabbit polyclonal antiserum specific for melanoma cancer cells was kindly donated by Dr. John R. Ortaldo from the National Cancer Institute. Maximum ADCC was produced when this antiserum was used at a 1/100 dilution. The second antibody target combination consisted of chicken red blood cells (CRBC) and a rabbit polyclonal antiserum specific for CRBC. (Organon Teknika-Cappell Laboratories). Maximum ADCC was produced when this antiserum was used at a 1/6,000 dilution.
Masking oftarget cell membrane antigens with monoclonal antibodies. Before the NK assay, 5'Cr-labeled target cells (25, Enzyme digestion of effectors. In certain experiments, effectors used in ADCC or NK assays were digested with pronase (Type XIV; Sigma Chemical Co., St. Louis, MO) as previously described (24) .
Pronase was used at a final concentration of 2 mg/ I0' lymphocytes/ml.
After incubation with this enzyme for 30 min at 370C, cells were washed twice with heat-inactivated FCS and resuspended in RPMI containing 10% FCS. Cell viability determined by trypan blue exclusion was > 85%. Efficacy of digestion was ascertained by indirect immunofluorescence as previously described (24) Target binding assay (conjugateformation). To observe binding of NK cells to their targets (conjugate formation), we used the method of Grimm and Bonavida (25) . 1 X 106 nonadherent (plastic petri dish) PBMC were mixed with 0.5 X 106 targets in a total volume of 1 ml culture medium (RPMI with 15% FCS). The cell mixture was gently centrifuged at 250 g for 5 min and then incubated for 30 min at 370C in a 5% CO2 humidified atmosphere. Cells were gently resuspended and 200 effector cells were counted. The percent binding of effectors to targets was calculated as follows: number of single effectors bound to single targets divided by the total number of effectors by 100%.
Single cell assayfor NK lysis. Effector cell lysis ofbound target cells was evaluated in the single cell assay for killing according to the method ofGrimm and Bonavida (25) . 1 X 106 nonadherent PBMC (in 0.5 ml) were mixed with 1 X 106 targets (in 0.5 ml). The cell suspension was gently centrifuged (250 g for 5 min) and then allowed to incubate in 5% CO2 for 30 min at 370C. After the incubation, cells were gently resuspended and then added to I ml of a 0.5% agarose solution maintained in liquified state at 420C. The cell agarose solution was pipetted on a 60-mm tissue culture plate and allowed to solidify at room temperature. The agarose was then overlaid with RPMI and incubated at 370C. After 2 h, medium was aspirated and 2 ml of 0.2% trypan blue added. The plates were then examined under an inverted microscope with phase contrast. The percentage of dead target cells in conjugates was calculated by counting 100 conjugates and evaluating number of conjugates with dead targets.
Lysis of tumor targets with large granular lymphocytes (LGL) granules. Granules from rat LGL were kindly provided by Dr. Pierre Henkart (Immunology Branch, NCI, Bethesda, MD). We followed previously described technique (26).
LGL granules (RNK 7P7A, 7,500 U/ml) was diluted in PBS without calcium. 200 lambda of granules with the desired cytolysin activity was added to 200 lambda 5"Cr labeled tumor targets (2 X (Table I, Table II, initially interacted with mouse monoclonal antibodies specific for either class I or II HLA antigens, so as to "block" or mask these cell membrane determinants. Target cells were washed to remove unbound antibody before coculturing them with effectors in the NK assays. Washing oftarget cells after antibody pretreatment was essential as this procedure (a) decreased or prevented antibody interaction with effector cells and (b) removed preservatives or proteases that can be present in monoclonal antibody supernatants, thus reducing nonspecific effects on effectors and targets. From Fig. 1 and Table II , it is evident that when HLA antigens were present on tumor target cells, binding of anti-HLA antibody to the target cells led to enhanced NK lysis. This was particularly true for lymphoblastoid cell lines and to a lesser extent with solid tumor cell lines. SK-MEL-1 was particularly resistant to NK lysis despite use of several monoclonals directed at class I determinants. Similar enhancement in lysis was observed with freshly obtained allogenic leukemic cells (data not shown). Secondly, there was heightened lysis of cell lines lacking HLA antigens (e.g., K562, Y79). Pretreatment with anti-HLA monoclonals did not increase the already enhanced lysis.
For optimal "masking" ofHLA antigen determinants, murine monoclonals had to be used at concentrations of0.5 to 1.0 ,ug per 25,000 targets although some enhancement of the NK lysis was observed with less quantities of monoclonal antibody (Fig. 4) . Of particular importance, to observe some enhancement of NK lysis, one required more antibody than that required to detect antibody binding by indirect immunofluorescence, i.e., by at least two more dilutions (a factor of four).
Effect ofmasking non-HLA determinants on tumor targets in the NK assay. It became important to determine if the observed enhancement of NK lysis was unique to masking of HLA determinants on tumor targets. 15 IgG 2a) ; and leukocyte determinants, leukocyte Common Antigen (CD45, IgG 1). As exemplified on Table III , no enhancement of NK lysis was observed after using monoclonals reactive to these non-HLA determinants.
Effect ofmasking HLA determinants on normal cell targets in the NK assay. We observed no NK lysis of normal autologous and allogenic lymphocytes (Fig. 1) , and enriched B lymphocytes and platelets (data not shown), despite the presence of these anti-HLA monoclonals. Similarly, normal allogeneic lymphocytes subjected to blast transformation with pokeweed mitogen or concanavalin-A were resistant to NK lysis despite presence of anti-HLA monoclonals. No conjugate formation was observed between these blasts and NK effectors. This latter observation would indicate that normal well differentiated lymphocytes, despite being allogeneic, are not lysed by NK cells even after blast transformation and masking of HLA antigens with monoclonal antibodies.
Importance of class I or II HLLA molecules and their epitopes in preventing NK lysis. As exemplified in Fig. 1 (anti-DR and DP, IgG 1) ICN (anti-DR, IgG 2a), 2.06 (anti-DR, Ig G1) as well as to some monoclonals reactive to polymorphic determinants of the HLA molecule, i.e., BB7.6 (anti-HLA-BW6, IgG 1), BB7.2 (anti-HLA-A2, IgG 2b). By indirect immunofluorescence all these nonenhancing antibodies were strongly reactive to the targets tested. The ability of only certain anti-HLA monoclonals to enhance NK lysis suggests that certain epitopes present on the HLA monomorphic determinants and the beta-2-microglobulin are important in rendering target cells resistant to NK lysis.
Effect ofmasking HLA determinants on effectors in the NK assay. It is possible that enhanced NK lysis may result from monoclonal antibody effect on HLA antigens present on effectors. We did not feel that this was the case as targets pretreated with antibody were washed before co-culturing with effectors. Further, using K562 and Y79 targets, which lack both class I and II HLA molecules, no enhancing effect was observed even when NK assays were performed with effectors pretreated with anti-HLA sera and then washed or with anti-HLA sera being present throughout the NK assay.
Studies to evaluate effectors responsible for enhanced NK lysis. It became important to determine whether the enhanced lysis observed in the presence of anti-HLA antibody was indeed mediated via NK effectors. Since the majority ofNK cells have CD16 phenotype (with some cells coexpressing CD8) (22) , experiments were repeated with effectors depleted ofcells with such phenotypes using a complement-dependent lysis system. Data in Table IV lysis after pretreating targets with anti-HLA antibodies, studies were conducted with purified LGL granules. Data in Table VI indicate that the anti-HLA monoclonals did not increase the susceptibility of the tumor targets to the LGL granules. It is, therefore, possible that the enhanced postbinding lysis (after pretreating targets with anti-HLA antibodies) results from enhanced triggering of NK effector cells when HLA antigens on tumor targets are masked by the antibody. Experiments to exclude the possibility ofADCC. It is possible that the enhanced NK lysis oftumor targets observed in the presence of anti-HLA monoclonals are a result of ADCC and not NK lysis. ADCC did not, however, appear to be a satisfying explanation for our observations as it became difficult to explain why all anti-HLA murine monoclonals with similar isotypes did not lead to enhanced target cell lysis, despite demonstrating avid binding to HLA determinants. Additionally, under the conditions of the assay, none of the murine monoclonals binding to non-HLA determinants led to enhanced NK lysis (Table III) .
Three different experimental approaches were, however, performed to exclude the possibility of ADCC. Firstly, experiments were performed using effectors pretreated with pronase to digest FcIgG receptors, which are important in ADCC. In these experiments, as a control, we used a well-studied, ADCC-mediated lysis of tumor target using a rabbit antibody that binds to non-HLA antigen present on human melanoma cells (Table VII) (21). ADCC-mediated lysis of FeMx targets with the rabbit antibody was markedly reduced using pronase digested effectors, thus demonstrating that the FcIgG receptors were effectively digested. Despite FcIgG receptor digestion, enhanced lysis of tumor targets was not reduced in the NK system with antibodies (both monoclonal and alloantibodies) that bound to HLA determinants on tumor targets. This lack of inhibition cannot be explained on the basis of increased affinity of murine IgG to partially digested human FcIgG receptors as data in Fig. 2 would argue against this possibility. Binding affinity of the various animal IgG to human FcIgG was compared by elucidating the binding of lymphocytes to serum IgG as previously described (27) . As can be seen from Fig. 2 , rabbit, but not murine IgG bound very avidly to human FcIgG receptors present on lymphocytes. Hence, ADCC resulting from partially digested or undigested FcIgG receptors should have been evident with the rabbit antibody, which has a higher affinity for the receptors. 5"Cr labeled cell lines were incubated with the various anti-HLA mouse monoclonals (L243 anti-DR, W6/32 anti-HLA-AB), washed and then exposed to LGL granules. 2 X 104 targets in 0.2 ml RPMI (with Hepes buffer) were interacted with 0.2 ml LGL granules having varying cytolysin activity. 1 LU of LGL granule is defined as the amount of cytolysin that will cause 50% lysis of a 1-ml suspension containing 0.2% SRBC.
In the second series of experiments (FabY2 fragments of antibody were used to mask HLA determinants on tumor targets as the Fc portion of IgG is essential to mediate ADCC. It was not possible in our laboratory to obtain (Fab)'2 fragments of murine monoclonals W6/32, L243, and L368 without affecting their binding avidity to cell membrane determinants and without significant Fc contamination despite using pepsin digestion techniques described by Parham (28) . Our experience has been shared by other investigators who have demonstrated rapid degradation of the (Fab)2 monoclonal proteins (29, 30) . Hence, (Fab)'2 fragments of human anti-HLA antibodies were used. Fig. 3 exemplifies data from two of the five alloantibodies. As illustrated in the bottom two panels, there was significant enhancement in NK lysis with (Faby2 anti-HLA alloantibodies even when used in dilutions containing no intact FcIgG anti-HLA alloantibody. One cannot attribute the enhanced NK lysis to ADCC mediated by contaminating intact FcIgG anti-HLA antibodies that cannot be detected by indirect immunofluorescence mainly because to observe any enhanced NK lysis in our experimental system significant amounts of FcIgG antibody had to be present. As depicted in the top panel of Fig. 3 , enhanced NK lysis was not observed even when by indirect immunofluorescence there was enough FcIgG binding to 60% of cells.
Because of the inability to prepare (Fab)2 fragments with the mouse monoclonals, another technique was utilized to prevent the Fc portion of the antibody from binding to Fc receptors present on effectors. This was accomplished with SpA, which several investigators have used to effectively inhibit ADCC (31) (32) (33) . In control experiments, another wellstudied ADCC mediated lysis of targets was used, i.e., lysis of CRBC with rabbit anti-CRBC antibody. The rabbit anti-FeMx system could not be used because of weak binding of FITC SpA to this antibody. Experiments using SpA to inhibit ADCC demonstrated that SpA inhibited ADCC mediated by rabbit anti-CRBC but did not inhibit enhanced NK lysis mediated by the anti-HLA monoclonals (Fig. 4) despite avid binding of SpA to the anti-HLA monoclonals (Fig. 5) .
Discussion
Data from the present investigations indicate that MHC gene products are important in maintaining resistance of tumor targets to NK lysis as has been proposed by others (4-7). Unlike other investigators, we utilized a somewhat direct approach by employing monoclonal antibodies to HLA determinants to alter or mask the amount of MHC determinants on the tumor target cells. Our studies indicate that class II HLA determinants also impart resistance to tumor targets against NK-mediated lysis. Previous studies have mainly focused on the protective role of class I antigens as their techniques did not allow for studying class II antigens (4-7). When tumor targets express both class I and II molecules, then NK lysis is (middle and lower panels) of anti-HLA alloantibodies, washed and then subjected to NK lysis. The purity of F(ab')2 fragments is illustrated by indirect immunofluorescence using FITC F(ab')2 goat antihuman IgG (Fc specific) (flow cytometry) to show alterations in their expression of MHC gene products, it is possible that reduced expression may allow tumor cells to escape detection by cytotoxic T lymphocytes as has been previously proposed (37) . NK effectors may have evolved to prevent the growth or expansion of tumor cells that have escaped T cell recognition, a hypothesis that has been put forward by Karre and his colleagues (4).
